NextCure, Inc. (NXTC)
6.39
+0.30
(+4.93%)
USD |
NASDAQ |
Aug 31, 16:00
6.27
-0.12
(-1.88%)
After-Hours: 06:41
NextCure Max Drawdown (5Y) : 99.29% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 99.29% |
| July 31, 2026 | 99.29% |
| June 30, 2026 | 99.29% |
| May 31, 2026 | 99.29% |
| April 30, 2026 | 99.29% |
| March 31, 2026 | 99.29% |
| February 28, 2026 | 99.29% |
| January 31, 2026 | 99.29% |
| December 31, 2025 | 99.29% |
| November 30, 2025 | 99.29% |
| October 31, 2025 | 99.29% |
| September 30, 2025 | 99.29% |
| August 31, 2025 | 99.29% |
| July 31, 2025 | 99.29% |
| June 30, 2025 | 99.29% |
| May 31, 2025 | 99.29% |
| April 30, 2025 | 99.29% |
| March 31, 2025 | 98.88% |
| February 28, 2025 | 98.88% |
| January 31, 2025 | 98.88% |
| December 31, 2024 | 98.88% |
| November 30, 2024 | 98.88% |
| October 31, 2024 | 98.88% |
| September 30, 2024 | 98.88% |
| August 31, 2024 | 98.88% |
| Date | Value |
|---|---|
| July 31, 2024 | 98.88% |
| June 30, 2024 | 98.88% |
| May 31, 2024 | 98.88% |
| April 30, 2024 | 98.88% |
| March 31, 2024 | 98.88% |
| February 29, 2024 | 98.88% |
| January 31, 2024 | 98.88% |
| December 31, 2023 | 98.88% |
| November 30, 2023 | 98.88% |
| October 31, 2023 | 98.88% |
| September 30, 2023 | 98.70% |
| August 31, 2023 | 98.70% |
| July 31, 2023 | 98.70% |
| June 30, 2023 | 98.70% |
| May 31, 2023 | 98.70% |
| April 30, 2023 | 98.70% |
| March 31, 2023 | 98.70% |
| February 28, 2023 | 98.70% |
| January 31, 2023 | 98.70% |
| December 31, 2022 | 98.70% |
| November 30, 2022 | 98.58% |
| October 31, 2022 | 97.41% |
| September 30, 2022 | 97.05% |
| August 31, 2022 | 96.33% |
| July 31, 2022 | 96.33% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -57.05 |
| Beta (5Y) | 1.330 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 124.1% |
| Historical Sharpe Ratio (5Y) | -0.3625 |
| Historical Sortino (5Y) | -0.8423 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 38.08% |